EUVIMEDEUVIMED entdecken
Open Access · CC0

The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors

Eun-Jeong Yu iD, Daphne W Bell iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0312806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Eun-Jeong Yu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Cancer Genetics Section, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes …. Hauptthemen laut MEDLINE: Receptor, Transforming Growth Factor-beta Type I, Protein Serine-Threonine Kinases, Signal Transduction, Receptors, Transforming Growth Factor beta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Intramural NIH HHS, National Human Genome Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ALK5 (TGFBR1) receptor serine/threonine kinase transduces TGF-β (Transforming Growth Factor beta) signaling to activate SMAD2/3-dependent and -independent pathways. Here, we aimed to determine the functional consequences of ALK5 mutations in human endometrial cancer (EC). Somatic mutation data were retrieved from publicly available databases. Using seven in silico algorithms, 78.5% (11 of 14) of ALK5 kinase domain mutations in EC, including A230V-ALK5, were predicted to impact protein function. For in vitro studies, we focused on A230V-ALK5 because it was the only mutated residue located within the ATP-binding pocket, which is an important region for both ATP-binding and binding of ATP-competitive inhibitors. Constructs expressing wildtype-, constitutively-active-, kinase-dead-, or mutant A230V-ALK5, were transfected into NIH/3T3 cells. Following TGF-β1 stimulation, transient exogenous expression of A230V-ALK5 resulted in attenuated SMAD2/3 signal transduction and reduced AKT activation. We further showed that the A230V-ALK5 mutant had reduced stability resulting from increased ubiquitin-dependent protein degradation. Our structural modeling predicted that SB-431542, a small molecule ATP-competitive inhibitor of ALK5, binds to the A230V-ALK5 mutant with reduced affinity compared to wildtype-ALK5. We therefore examined the inhibitory effect of SB-431542 and galunisertib on wildtype- and mutant-ALK5 activity using a Smad-binding element (SBE) luciferase reporter assay combined with TGF-β1 stimulation, in NIH/3T3 cells and HEC-265 EC cells. SBE luciferase activity in A230V-ALK5 transfected cells was inhibited less by SB-431542 and galunisertib than in wildtype-ALK5 transfected cells indicating that A230V-ALK5 is less sensitive to inhibition by these agents than wildtype-ALK5, potentially due to changes in SB-431542/A230V-ALK5 binding affinity. Our findings are novel and show that A230V-ALK5 is a partial loss-of-function mutant that attenuates TGF-β1 signal transduction and has reduced sensitivity to ALK5 small molecule inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Transforming Growth Factor-beta Type IProtein Serine-Threonine KinasesSignal TransductionReceptors, Transforming Growth Factor betaEndometrial NeoplasmsHumansFemaleAnimalsMiceCell Line, TumorMutationTransforming Growth Factor betaProtein Kinase InhibitorsSmad2 ProteinBenzamidesNIH 3T3 CellsQuinolinesPyrazolesSmad3 Protein

Substanzen

Receptor, Transforming Growth Factor-beta Type ITGFBR1 protein, humanProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaTgfbr1 protein, mouseTransforming Growth Factor betaProtein Kinase InhibitorsSmad2 ProteinBenzamidesLY-2157299

Autor:innen und Institutionen

  • Reproductive Cancer Genetics Section, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.

ORCID-Profile: Eun-Jeong Yu, Daphne W Bell

Förderung

  • Intramural NIH HHS
  • National Human Genome Research Institute

Zitieren

APA

Yu, E. J., & Bell, D. W. (2024). The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors. PLOS ONE. https://doi.org/10.1371/journal.pone.0312806

Vancouver

Yu EJ, Bell DW. The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors. PLOS ONE. 2024. doi:10.1371/journal.pone.0312806

BibTeX
@article{Yu2024,
  author = {Yu, Eun-Jeong and Bell, Daphne W},
  title = {The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0312806}
}
Kostenlos starten →